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CCL = CC chemokine ligand; CCR = CC chemokine receptor; CXCL = CXC chemokine ligand; CXCR = CXC chemokine receptor; IL = inter-
leukin; MCP = monocyte chemoattractant protein; RA = rheumatoid arthritis; SDF = stromal cell derived factor.
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Introduction
Chemokines form a large superfamily of small (8–14 kDa)
cytokines that play crucial roles in cell migration. They
interact with G-protein-coupled receptors, which possess
a seven transmembrane domain. To date about 50
chemokines have been identified that signal through some
20 distinct receptors [1].
A subset of the chemokine family is active under normal
physiological conditions. These so-called homeostatic
chemokines are involved in maintaining normal leucocyte
traffic and cell compartmentalization in lymphoid tissues
under non-inflammatory conditions [2].
Most chemokines play a role in inflammatory conditions by
inducing integrin activation, chemotaxis, and angiogenesis.
Apart from modulating migration directly, chemokines can
stimulate cells to release (pro)inflammatory mediators such
as cytokines and matrix metalloproteinases [3]. Increased
expression of inflammatory chemokines has been found in
many inflammatory disorders, including hepatic disease,
multiple sclerosis, transplant rejection and inflammatory
bowel disease [4]. Analysis of synovial tissue, synovial fluid
and peripheral blood from patients with rheumatoid arthritis
(RA) revealed abundant expression of a variety of
inflammatory chemokines and their receptors [5,6]. In vitro
studies have suggested that both so-called homeostatic
chemokines and inflammatory chemokines, including CC
chemokine receptor (CCR)1, CCR2, CCR5, CC
chemokine ligand (CCL)2/monocyte chemoattractant
protein (MCP)-1, CCL5/RANTES (regulated on activation,
normal T-cell expressed and secreted) and CXCL8/IL-8,
are intimately involved in cell migration toward the synovial
compartment in RA [7–10].
Although these studies might suggest therapeutic
potential for chemokine and chemokine receptor blockade
in inhibiting chronic synovial inflammation, there are some
possible pitfalls that could hamper the clinical use of this
approach. Of particular importance is the redundancy of
the system, based on in vitro studies. Because one
receptor can usually bind multiple ligands and vice versa,
one may anticipate that blockade of one ligand or receptor
may be compensated for by other members of the
superfamily. In addition, some ligands may be agonists at
one receptor and antagonists at others. Another issue is
that one should not interfere with the role played by these
molecules in normal homeostasis.
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Abstract
Blockade of chemokines or chemokine receptors is emerging as a new potential treatment for various
immune-mediated conditions. This review focuses on the therapeutic potential in rheumatoid arthritis,
based on studies in animal models and patients. Several knockout models as well as in vivo use of
chemokine antagonists are discussed. Review of these data suggests that this approach might lead to
novel therapeutic strategies in rheumatoid arthritis and other chronic inflammatory disorders.
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Recently, there has been an enormous upsurge in
investigations on the potential of chemokine blockade as a
novel therapeutic strategy to inhibit inflammation because
of the advent of new biotechnology-derived antagonists.
Many biological agents as well as small molecules that
target chemokines and chemokine receptors are currently
in clinical development [11].
This review focuses on the available in vivo data, which
may provide more insight into the chances that disrupting
one single factor of the complicated chemokine network
could be clinically effective in chronic inflammatory
disorders such as RA.
Lessons from knockout models
Because of apparent overlapping biological activities in
vitro, it is difficult to determine the precise role of specific
chemokine–chemokine receptor interactions in vivo. Gene
deletion approaches have proved particularly useful in
dissecting the physiological role played by specific
chemokines and chemokine receptors. To date various
models of receptor and ligand deletion have been
reported [12].
Only one (homeostatic) chemokine receptor knockout
mouse model was shown to lead to perinatal death,
namely the CXC chemokine receptor (CXCR)4 knockout
mouse [13]. Deletion of its only known ligand, CXC
chemokine ligand (CXCL)12/stromal cell derived factor
(SDF)-1α, yielded a phenotype similar to that in the
CXCR4 knockout mouse. Although under normal,
unchallenged circumstances most chemokine receptor
knockout mice are healthy, suggesting compensation by
chemokine receptor family members, it is clear that they
have an altered immune system. Chemokine receptor
knockout mice are more susceptible to infections, for
instance with Aspergillus fumigatus and  Listeria
monocytogenes, than are their wild-type counterparts
[14,15]. Moreover, in some disease models deleting
chemokine receptor genes appears to have a protective
effect; for example, CCR2 knockout mice are resistant to
experimental autoimmune encephalitis, and CCR1
knockout mice had prolonged allograft survival in a cardiac
transplant model [16,17].
Only a few knockouts have been used in arthritis models.
CXCR2 was shown to be important for neutrophil
migration in a model of acute gout [18]. In that study urate
crystals were injected into subcutaneous air pouches. In
mice that lacked the murine CXCR2 homologue urate
crystals induced a leucocyte-poor exudate. The same
receptor also proved to be important in neutrophil
recruitment in Lyme arthritis. Infection of CXCR2–/– mice
with Borrelia burgdorferi resulted in a significant decrease
in severity of arthritis but had little effect on spirochete
loads in joint tissue [19]. In contrast, infection of CCR2–/–
mice in the same model had little effect on the
development of arthritis or on spirochete clearance. The
notion that this might be accounted for by redundant
recruitment mechanisms is supported by the observation
that monocytes were still present within the inflammatory
infiltrates in the joints of the CCR2–/– mice [19].
Data from the knockout mice suggest that at least some
individual inflammatory chemokine receptors are pivotal in
the inflammatory process in both infections and immune-
mediated disorders.
Chemokine blockade in animal models
In addition to knockout models, which may help to identify
potential targets, blocking studies with neutralizing
antibodies or small molecules could provide insight into
the overlapping and distinct effects of chemokines and
their receptors. Furthermore, animal models can be used
to assess the role of several pathogenic factors at various
stages of disease, and thus may serve as a sophisticated
tool with which to study the relevance of individual
chemokines and chemokine receptors in vivo.
Despite the availability of multiple highly specific
compounds, species specificity of small molecules and
neutralizing antibodies complicates the use of these
compounds in animal models. Nevertheless, various
chemokines and chemokine receptors have been targeted
successfully in animal models of arthritis. Studies using
this approach suggest that redundant recruitment
mechanisms do not necessarily exclude the possibility that
biological and clinical effects may occur after specific
chemokine blockade.
For instance, a study using specific blockade of
CXCL8/IL-8, an important stimulant of neutrophil
accumulation in acute inflammation, showed that it is
possible to block neutrophil migration selectively [20]. In
that study a highly specific neutralizing antibody against
IL-8 was administered in several types of acute
inflammatory disease, including lipopolysaccharide/IL-1
induced arthritis. Anti-IL-8 treatment prevented neutrophil
infiltration and resulting tissue damage, despite the fact
that CXCL8/IL-8 is also a known ligand for CXCR1,
which may be present at high concentrations in the
synovial compartment.
Similarly, injection of a specific neutralizing monoclonal
antibody against rat CCL2/MCP-1 in rats with collagen-
induced arthritis resulted in reduced ankle swelling, in
association with decreased macrophage numbers in the
joints [21]. Paw swelling of the hindfeet in the antirat
MCP-1 treated rats was decreased to about 70% of that
in untreated rats. Moreover, destruction of the joints was
significantly reduced. This was confirmed in the MRL/lpr
mouse model of RA. In MRL/lpr mice that spontaneously95
develop chronic inflammatory arthritis, daily injection of the
antagonist MCP-1(9–76) prevented the onset of arthritis
whereas controls treated with native MCP-1 had
enhanced arthritis symptoms [22]. Of importance for
clinical use, there was also a marked reduction in
symptoms and histopathology if the antagonist was given
only after the disease had already developed. The
protective effect on cartilage and bone destruction might
be explained in part by the fact that CCL2/MCP-1 is able
to stimulate matrix metalloprotease-3 [23].
The CXCR4–CXCL12/SDF-1α complex appears to be
another interesting target. Because CXCL12/SDF-1α only
recognizes a single receptor (i.e. CXCR4), which itself is
only recognized by CXCL12/SDF-1α, and because the
deletion of CXCR4 has dramatic effects on the
phenotype, targeting this molecule in animal models is
expected to have significant effects. Blockade of CXCR4
with a synthetic, nonpeptide antagonist that does not
crossreact with other chemokine receptors exerted clear
beneficial effects, both histopathologically and clinically, in
murine collagen-induced arthritis [24]. Clinical improve-
ment was also achieved when treatment was initiated at
the time of disease onset. Apparently, this effect was
solely due to inhibition of migration of CXCR4+MAC-1+
cells through the interference with the chemotactic activity
of CXCL12/SDF-1α.
CCR5 attracted much attention as a potential therapeutic
target for treatment of HIV infection. A nonpeptide
antagonist of this chemokine receptor, namely TAK-779,
has also been tested in murine collagen-induced arthritis
[25]. Subcutaneous treatment with the CCR5 antagonist
initiated a few days before clinical signs of arthritis
developed markedly reduced the incidence and severity of
the disease, in association with significantly decreased
leucocyte migration to the joints.
Taken together, these studies in animal models of arthritis
suggest that specific chemokine (receptor) blockade may
result in clinically meaningful effects, despite the large
number of chemokine family members and their existing
overlapping functions. It should be stated, however, that
the data are still limited. It remains to be shown whether
long lasting effects can be achieved, because it is
conceivable that compensatory feedback systems need
more time to become effective.
Experience in patients
Data on the effects of chemokine blockade in patients are
still very limited. The area is still relatively new, and it is
difficult to assess the effectiveness of some of the
compounds in animal models because of species
selectivity, which could delay development. In addition,
development may be hampered by low oral bioavailability
of some of the compounds [26,27].
It has recently been suggested that treatment with a
monoclonal antibody against CXCL8/IL-8 was not
effective in a phase II study in RA patients [28]. It is
difficult to interpret the results of that study because the
full dataset has not yet been disclosed.
The only published study on chemokine receptor blockade
in patients with chronic inflammatory disease to date is a
relatively small phase Ib study in RA patients using a
CCR1 antagonist [29]. CCR1-positive cells are scattered
throughout the rheumatoid synovium, and most of the
CCR1-positive cells are macrophages, which play a key
role in synovial inflammation. The rationale for the clinical
study was supported by interesting properties of the novel
small-molecular-weight CCR1 antagonist CP-481,715,
which was shown to inhibit 90% of the monocyte
chemotactic activity present in the synovial fluid of the
majority of RA patients [30]. In a randomized study
patients with active RA were treated for 2 weeks with a
highly specific CCR1 antagonist or placebo [29]. Synovial
tissue analysis revealed a marked decrease in the total
number of cells, especially in the number of macrophages
and CCR1+ cells after treatment (Fig. 1). Because only
cells capable of expressing CCR1 were affected, the
results confirmed the specificity of the antagonist and
showed the potential of selective chemokine receptor
blockade in RA. Although the study was not designed to
evaluate clinical efficacy, initial data were promising
because one-third of the patients fulfilled the ACR20%
criteria after active treatment.
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Figure 1
Representative synovial tissue before and after specific CC chemokine
receptor (CCR)1 blockade for 14 days in a patient with rheumatoid
arthritis (haematoxylin–eosin staining; original magnification ×400).
After active treatment there was a marked reduction in synovial
cellularity, which was not observed in patients who received placebo.
The reduction in cell infiltration was due to a specific decrease in
CCR1-positive cells [29].96
The data from studies with chemokine antagonists in
humans are at present not very comprehensive. However,
the initial data are promising. It can be anticipated that
several clinical trials exploring this approach will be
reported in the near future.
Conclusion
The available data in animal models and initial data in
human disease suggest that chemokine family members
might be attractive targets for therapeutic intervention.
Targeting one specific chemokine (receptor) could be
sufficient to reduce inflammation, despite the apparent
redundancy of the system. Theoretical advantages of the
use of small molecules serving as chemokine receptor
antagonists include oral delivery, controllable safety issues
during infection in light of the short half-life (the drug could
be discontinued during infection, allowing inflammatory
cells to migrate to the site of infection), and the potential
of inhibiting the migration of cells that are able to produce
an array of proinflammatory cytokines at the site of
inflammation.
The identification of the best targets will be the subject of
future research. It appears likely that redundant
mechanisms may be more important for some
chemokines than for others. For some pathways it might
be necessary to use poly-chemokine antagonists [11] or
to combine different chemokine antagonists. It can be
expected that rapid developments in immunology,
molecular biology and biotechnology will lead to an
increase in the number of chemokine and chemokine
receptor antagonists that can be tested in clinical trials.
Therefore, there is a clear need for biomarkers that could
be used for selection purposes during the development
process. We have previously proposed examination of
serial synovial samples as a method that can be used to
examine the effects of targeted antirheumatic
interventions [31]. This approach could be particularly
helpful in studies evaluating the effects of treatment
aimed at blocking cell migration to the site of
inflammation. It is likely that we will also see the
development of other forms of molecular imaging to
assist in selection of therapeutic targets.
A possible concern is that some chemokine ligands may
act as agonists rather than as antagonists [32].
Additionally, migration of cells with anti-inflammatory
properties could be inhibited by some forms of chemokine
blockade. This notion is supported by the observation that
CCR2 knockout mice had exacerbated disease in a model
of glomerulonephritis [33]. In addition, it remains to be
shown whether sustained clinical efficacy can be achieved
over time. Therefore, initial proof-of-principle studies
followed by well controlled studies of sufficient duration
will be essential to realise the potential of chemokine
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